Last reviewed · How we verify
Haplo-cord HCT
Haplo-cord HCT is a hematopoietic stem cell transplantation product derived from haploidentical cord blood designed to reconstitute hematopoietic and immune function.
Haplo-cord HCT is a hematopoietic stem cell transplantation product derived from haploidentical cord blood designed to reconstitute hematopoietic and immune function. Used for Hematologic malignancies requiring stem cell transplantation, Severe aplastic anemia.
At a glance
| Generic name | Haplo-cord HCT |
|---|---|
| Sponsor | The First Affiliated Hospital of Soochow University |
| Drug class | Hematopoietic stem cell therapy |
| Modality | Biologic |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a cellular therapy utilizing haploidentical (half-matched) umbilical cord blood stem cells for transplantation. The product aims to provide hematopoietic reconstitution with reduced graft-versus-host disease risk through the use of cord blood-derived cells, which have immunological properties that may be more tolerant than bone marrow-derived cells.
Approved indications
- Hematologic malignancies requiring stem cell transplantation
- Severe aplastic anemia
Common side effects
- Graft-versus-host disease
- Infection
- Engraftment failure
- Hematologic toxicity
Key clinical trials
- Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients (PHASE3)
- Haplo HCT vs Haplo-cord HCT for Patients With AML (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |